Hydrogels that degrade under appropriate conditions of pH and temperature by virtue of crosslinking compounds that cleave through an elimination reaction are described. The hydrogels may be used for delivery of various agents, such as pharmaceuticals.

Hydrogels that degrade under appropriate conditions of pH and temperature by virtue of crosslinking compounds that cleave through an elimination reaction are described. The hydrogels may be used for delivery of various agents, such as pharmaceuticals.

A method of applying a topical treatment of chemotherapy-induced peripheral neuropathic pain with a pharmaceutical composition comprising from 10% to 30% by weight of amitriptyline or of a pharmaceutically acceptable salt or ester thereof, relative to the total weight of the composition, amitriptyline, for use in the topical treatment of.

A method of applying a topical treatment of chemotherapy-induced peripheral neuropathic pain with a pharmaceutical composition comprising from 10% to 30% by weight of amitriptyline or of a pharmaceutically acceptable salt or ester thereof, relative to the total weight of the composition, amitriptyline, for use in the topical treatment of.

The present invention relates to compositions and methods for T cell targeted delivery of nucleoside modified mRNA molecules encoding agents for the treatment and prevention of fibrosis, cardiac disease, and diseases and disorders associated therewith.

Disclosed is a bolus for oral administration to an animal, the bolus comprising at least one beneficial substance to be delivered to the animal, the bolus comprising two components which are adhered together by a water-soluble adhesive or sealant, such that the two components are separable in vivo, and wherein at least one of the aforesaid components is frangible in vivo, the frangible component being initially stabilised by the adherence thereto of the other of the aforesaid components, such that separation of the two components in vivo facilitates the breakage of the frangible component.

Disclosed is a bolus for oral administration to an animal, the bolus comprising at least one beneficial substance to be delivered to the animal, the bolus comprising two components which are adhered together by a water-soluble adhesive or sealant, such that the two components are separable in vivo, and wherein at least one of the aforesaid components is frangible in vivo, the frangible component being initially stabilised by the adherence thereto of the other of the aforesaid components, such that separation of the two components in vivo facilitates the breakage of the frangible component.

A pharmaceutical composition comprising dabigatran etexilate, and preparation method and use thereof, and solid preparation comprising the pharmaceutical composition; the pharmaceutical composition comprises a vitamin C layer and a dabigatran etexilate layer separated by a semipermeable film layer, and the semipermeable film layer comprises a water-soluble compound, a water-insoluble compound and an optional anti-sticking agent and/or plasticizer.

A pharmaceutical composition comprising dabigatran etexilate, and preparation method and use thereof, and solid preparation comprising the pharmaceutical composition; the pharmaceutical composition comprises a vitamin C layer and a dabigatran etexilate layer separated by a semipermeable film layer, and the semipermeable film layer comprises a water-soluble compound, a water-insoluble compound and an optional anti-sticking agent and/or plasticizer.

The present invention relates generally to a hydrogel releasing glucose in a time-controlled manner, to medical applications thereof, and to a method for preparing said hydrogel.